Table 1 Patient characteristics according to ELN-2022 risk groups.

Patients, n

1 118

363

302

453

–

Age, median (range)

58 (18–86)

52 (18–86)

55 (18–83)

62 (21–80)

<0.0001

Male sex

573

166

133

274

0.003

 De-novo AML

937

334

258

345

–

 Secondary AML

124

17

27

80

0.0006

 Therapy-related AML

57

12

17

28

0.2126

 WBC at diagnosis [G/l], median (range)

20.4 (0.1–798)

24.1 (0.4–798)

36.5 (0.1–786)

11.5 (0.5–666)

<0.0001

 Bone marrow blasts [%], median (range)

80 (6–100)

80 (6–100)

83 (10–100)

71 (9–100)

0.002

 Favorable

423

351

61

11

–

 Intermediate

295

7

220

68

–

 Adverse

400

5

21

374

–

 ASXL1

135

14

2

119

<0.0001

 BCOR

90

6

3

81

<0.0001

 CEBPA^bZIP-inf

44

44

0

0

0.0001

 CEBPA^other

39

8

18

13

0.4085

 DNMT3A

391

137

157

97

0.0022

 EZH2

44

11

1

32

0.0002

 FLT3-ITD

303

14

204

85

0.0032

 FLT3-ITD low

131

11

78

42

0.0374

 FLT3-ITD high

172

3

126

43

0.0114

 IDH1

98

43

29

26

0.0034

 IDH2

165

43

48

74

0.2308

 KMT2A-PTD^a

56

1

17

38

0.0028

 KRAS

73

26

19

28

0.7133

 NPM1

431

239

164

28

<0.0001

 NRAS

216

98

39

79

0.1902

 PTPN11

114

59

18

37

0.0699

 RAD21

54

27

17

10

0.0006

 RUNX1

178

7

0

171

0.0087

 TET2

192

65

51

76

0.8087

 TP53

81

2

4

75

<0.0001

 SF3B1

45

4

1

40

<0.0001

 SRSF2

135

21

1

113

<0.0001

 STAG2

98

17

1

80

0.0075

 U2AF1

38

3

0

35

0.0016

 WT1

143

48

43

52

0.2756

 ZRSR2

12

2

0

10

0.0005